Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New Post-Hoc Analyses Show Januvia™ (sitagliptin) Provided Significant Blood Sugar Lowering Sustained Over Two Years
New post-hoc analyses, presented at the American Diabetes Association (ADA) 69th Annual Scientific Sessions, of data pooled from studies of 104 weeks in duration showed "Januvia" (sitagliptin), when taken alone* (2 studies) or in combination with metformin (2 studies), provided significant blood sugar lowering, which was sustained over two years.[i]

Breast Cancer Help, Inc. Attends National Breast Cancer Coalition Annual Advocacy Conference In Washington, D.C.
As part of its community outreach, Breast Cancer Help, Inc. attended the annual National Breast Cancer Coalition (NBCC) conference, which was held May 2-5 at Washington, D.C. Representatives of Breast Cancer Help, along with hundreds of other activists, met at the nation"s capital to meet with elected officials who are responsible for the majority of the funding for breast cancer research. The conference was held to challenge the newly elected leaders in Washington to create the changes necessary to ensure the much-needed funding for research and access to quality care.
News of the day
CCA, AIMp And NPA Statement: Decriminalisation Of Dispensing Errors
The decriminalisation of dispensing errors is an issue that has united the profession.
Nutrition

Early Switch From Cyclosporine To Sirolimus After Renal Transplantation Produces Sustained Improvement In Renal Function

BOSTON - Favorable 12-month outcomes are maintained through 30 months of follow-up when renal transplant patients are converted from a cyclosporine (CsA)-based regimen to a sirolimus (SRL)-based regimen three months post-transplant, according to results of the CONCEPT study announced here at the American Transplant Congress (ATC) 2009. Yvon Lebranchu, MD, from the University FranÃýois Rabelais in Tours, France, reported 30-month results in patients who were initially treated with mycophenolate mofetil (MMF) plus cyclosporine (CsA) and then randomized three months later to continue this regimen, or CsA therapy was stopped and replaced by SRL. The trial included 192 first-time renal allograft recipients at 16 centers throughout France. "Long term use of CsA may contribute to the development of chronic allograft nephropathy," Dr. Lebranchu pointed out. "While earlier trials have demonstrated a positive impact of de novo SRL on renal function at one year post transplantation, adverse effects have limited the use of this approach." An analysis at 12 months in 181 patients found that glomerular filtration rate (GFR), as estimated by the simplified MDRD formula, was significantly better in the SRL group (61.9 mL/min versus 53.8 mL/min, p=0.0002). Improvement in renal function occurred without a significant increase in acute rejection. Thirty-month results in 152 patients in the intent-to-treat population showed an MDRD GFR of 58.3 mL/min and 52.6 mL/min in the two groups, respectively, p=0.027. This difference was more pronounced in patients on treatment: 64.4 mL/min and 53.8 mL/min in the two groups, respectively. Graft loss and patient survival were similar in the two treatment groups. One patient in the SRL/MMF group had developed a malignancy versus six patients in the CsA group. "Long-term maintenance of renal function is a challenge in renal transplant recipients, and the use of CNIs is associated with chronic long-term graft dysfunction," Dr. Lebranchu said. "The identification of strategies of CNI avoidance or elimination is extremely important." Sandi See Tai, MD, Director, Global Medical Affairs, Transplantation, Wyeth Pharmaceuticals, said that the data are encouraging "because they indicate better long-term outcomes for kidney transplant patients." Wyeth Pharmaceuticals markets sirolimus under the trade name RAPAMUNE®. "Overall, the interim results of CONCEPT show that a sirolimus-based regimen may provide lasting benefits in renal transplant patients," Dr. Lebranchu added. Written by Jill Stein Jill Stein is a Paris-based freelance medical writer. jillstein03(at)gmail.com Copyright: Medical News Today Not to be reproduced without permission of Medical News Today


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009